Shanghai Pharma and SIMM Sign Framework Agreement on Drug R&D and Commercialization
Shanghai Pharmaceuticals Holding Co. , Ltd. and the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences signed a framework cooperation agreement on September 7 to deepen collaboration in innovative drug research and development and the commercialization of research results. The partnership aims to integrate scientific research resources with industrial capabilities, establish a long-term cooperation mechanism, and accelerate the transition of laboratory innovations into industrial applications.
On September 7, Shanghai Pharmaceuticals Holding Co. , Ltd. and the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences signed a framework cooperation agreement. The two parties will engage in in-depth collaboration focused on innovative drug research and development and the commercialization of research outcomes, aiming to better align scientific research capabilities with industrial strengths and jointly improve the efficiency of translating innovative results into practical applications.
The cooperation is designed to combine the two institutions' research resources and industrial transformation capabilities in the pharmaceutical field. By establishing a long-term cooperation mechanism, the initiative seeks to facilitate the movement of more innovative outcomes from the laboratory to industrial application.